Owen Wallace

Company: Monte Rosa Therapeutics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: KOL Future Advisory Panel 9:30 am

At a time when the TPD community is poised for more clinical success yet continues to battle for available funding to progress this pioneering drug modality, its crucial we heed the knowhow and experience of the field’s thought leaders. Here we have our TPD Future Advisory Panel Where should the field’s focus be on tackling…Read more

day: Day 2 AM

Molecular Glue Degraders for Non-Oncology Indications 9:00 am

Molecular glue degraders (MGDs) have historically been developed for oncology indications Our platform has enabled programs in non-oncology indications, such as diseases associated with autoimmunity and inflammation An overview of the additional challenges associated with degraders for non-oncology diseases will be provided, together with updates on our programs highlighting our rational design of selective and…Read more

day: Day 2 AM